Search results
20 hours ago · The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases.
3 days ago · Nikki Morris, CEO of Deafblind UK. Deafblind UK was expanding its services for people impacted by Usher syndrome, including incorporating the Usher specialist team from the charity, Sense, to provide vital support. Deafblind UK would continue to support those affected by all types of Usher syndrome, including providing education, communication ...
3 days ago · Melanie was in her early 20s when she began noticing something was wrong with her vision. The Melbourne woman was working as a veterinary nurse at the time. "I started not to be able to see well ...
4 days ago · Usher syndrome (USH) is an autosomal recessive disorder characterized by retinitis pigmentosa and hearing loss. USH type 2 (USH2) is the most common type of USH and is frequently caused by mutations in USH2A. In a recent mutation screening of USH2A in Japanese USH2 patients, we identified 11 novel m …
20 hours ago · Kerstin Dolph, CSVP, Global Manufacturing, Charles River, commented in a press release announcing the collaboration: “Charles River is thrilled to produce GMP plasmid DNA to help advance AAVantgarde’s platform for the treatment of Stargardt's disease – a condition in which there is high unmet need. Our team brings more than two decades of ...
4 days ago · Glucose Transporter Protein Type 1 Deficiency Syndrome. Glut1 Deficiency is a rare genetic condition that impairs brain metabolism. Glucose isn't transported properly across the blood brain barrier and into the brain, preventing it from growing, developing, and functioning the way it should.
20 hours ago · There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available. With a new three-year, $1.5 million grant from the Foundation Fighting Blindness, Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at the Case Western Reserve University School of ...
